News

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
10/16/2019
4:15 PM ET
Press Release

Zymeworks Appoints Chief People Officer

10/16/2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the appointment of Kathryn O’Driscoll to the executive team as Chief People Officer (CPO).

 Continue Reading
9/28/2019
8:30 AM ET
Press Release

Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress

9/28/2019

Single Agent Activity and Durable Disease Control Across Multiple Tumor Types Data Support the Initiation of a Registration-Enabling Phase 2 Trial Evaluating Single Agent ZW25 in Second-Line HER2-Expressing Biliary Tract CancersBARCELONA, Spain--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated data from the ongoing multi-center Phase 1 clinical trial evaluating ZW25 in patients with HER2‑expressing solid tumors, including biliary tract cancer (BTC), colorectal cancer (CRC), gynecological cancers, and gastroesophageal adenocarcinoma (GEA), in a poster discussion presentation at the ESMO 2019 Congress, taking place September 27 - October 1 in Barcelona, Spain.

 Continue Reading
9/17/2019
6:45 AM ET
Press Release

Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX

9/17/2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors. Ms. Zoth succeeds Nick Bedford, who has retired from his functions as Chair and Board member. Mr. Bedford served as Board Chair since September 2004.

 Continue Reading
8/28/2019
5:00 PM ET
Press Release

Zymeworks to Participate in Upcoming Investor Conferences

8/28/2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will participate in three upcoming investor conferences.

 Continue Reading
8/2/2019
5:00 PM ET
Press Release

Zymeworks Reports 2019 Second Quarter Financial Results

8/2/2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019.

 Continue Reading
Displaying 1 to 5 (of 125 releases)